A provider-focused briefing on Alrex availability in 2026. Learn about supply dynamics, generic alternatives, prescribing implications, and patient access tools.
As an ophthalmologist, optometrist, or primary care provider prescribing Alrex (Loteprednol Etabonate 0.2%) for seasonal allergic conjunctivitis, you may be hearing from patients that they can't find their medication at the pharmacy. This briefing provides an up-to-date picture of Alrex availability, the factors driving access challenges, and practical strategies to help ensure your patients get the treatment they need.
As of March 2026, Alrex is not listed on the FDA Drug Shortage database or the ASHP Drug Shortages list. There is no formal, manufacturer-reported supply disruption for either brand-name Alrex or generic Loteprednol Etabonate 0.2%.
However, providers should be aware that practical access challenges exist. Brand-name Alrex has become increasingly difficult for patients to locate at retail pharmacies. This is driven primarily by the widespread adoption of generic Loteprednol Etabonate 0.2%, which has led many pharmacy chains to discontinue stocking the brand-name product.
Understanding the market evolution helps frame current availability:
The availability landscape has several implications for prescribers:
Unless there is a clinical reason to specify brand-name Alrex, prescribing generic Loteprednol Etabonate Ophthalmic Suspension 0.2% will improve your patients' ability to fill their prescriptions. Generic Loteprednol 0.2% meets the same FDA standards for bioequivalence and is typically available at most retail pharmacies.
If you write for "Alrex" without DAW (dispense as written), most pharmacies will automatically substitute the generic. However, explicitly prescribing the generic can reduce confusion and delays.
Many commercial payers and pharmacy benefit managers now require step therapy before covering ophthalmic corticosteroids for allergic conjunctivitis. Common first-step requirements include:
Documenting prior OTC antihistamine trial and failure in the patient's chart can expedite prior authorization when a corticosteroid like Alrex is clinically indicated.
Brand-name Alrex increasingly requires prior authorization. Generic Loteprednol Etabonate 0.2% is more commonly on preferred formulary tiers. When submitting prior authorization requests, emphasize:
To help contextualize the current situation for your practice:
Understanding the cost landscape helps when counseling patients:
For patients struggling with cost, our detailed resource on saving money on Alrex covers all available discount and assistance programs.
Several tools can help your practice and patients navigate availability challenges:
Medfinder allows providers and patients to check real-time pharmacy availability for Alrex and generic Loteprednol. Consider recommending this tool to patients at the point of prescribing, particularly during peak allergy season when local shortages are more common.
When Alrex or generic Loteprednol 0.2% is unavailable, consider these alternatives based on clinical severity:
For a comprehensive comparison, see our clinical guide to alternatives to Alrex.
The ophthalmic allergy treatment landscape continues to evolve. Key trends to watch:
While there is no formal Alrex shortage, practical access challenges are real and ongoing. The most impactful steps providers can take are prescribing generically, documenting step therapy compliance, and directing patients to tools like Medfinder for real-time availability information.
For patients who need additional support finding their medication, our provider-facing guide on helping patients find Alrex in stock offers a step-by-step workflow for your practice.
Related provider resources:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
